What are Vitamin K antagonist drugs?

Vitamin K antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting Vitamin K epoxide reductase (VKORC1)). 1 are currently marketed, with 5 more in clinical development.

What are the marketed Vitamin K antagonist drugs?

Marketed Vitamin K antagonist drugs include Vitamin K antagonist(warfarin).

Vitamin K antagonist

1 marketed 5 in Phase 3

This page covers all Vitamin K antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Vitamin K epoxide reductase (VKORC1), Vitamin K epoxide reductase, VKORC1.

Targets

Vitamin K epoxide reductase (VKORC1) · Vitamin K epoxide reductase · VKORC1

Marketed (1)

Vitamin K antagonist(warfarin) · Joon Bum Kim · Cardiovascular
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the vitamin K epoxide reductase enzyme, thereby reducing thrombin generation and blood clot formation.

Phase 3 pipeline (5)

Warfarin titrated to an INR of 2.5-3.0 · US Department of Veterans Affairs · Cardiovascular
Warfarin inhibits the synthesis of vitamin K-dependent clotting factors in the liver.
Warfarin-Natrium · University Hospital, Bonn · Cardiovascular
Warfarin-Natrium is an anticoagulant that inhibits vitamin K-dependent clotting factors.
warfarine - low molecular heparin · University Hospital, Limoges · Cardiovascular
Warfarin inhibits the synthesis of vitamin K-dependent clotting factors in the liver, preventing blood clot formation.
INR101 · Yunhe Pharmaceutical (Tianjin) Co., Ltd · Cardiovascular
INR101 is an anticoagulant that works by inhibiting the synthesis of vitamin K-dependent clotting factors.
Vitamin K antagonists (VKA) · Population Health Research Institute · Cardiovascular
Vitamin K antagonists inhibit the vitamin K-dependent gamma-carboxylation of clotting factors, leading to anticoagulation.